Vascepa vs Crestor
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Vascepa | US Crestor | |
|---|---|---|
| Generic name | icosapent ethyl | rosuvastatin |
| Drug class | Omega-3 Fatty Acid (EPA) | Statin |
| Treats | High triglycerides, cardiovascular risk reduction | High cholesterol, cardiovascular prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amarin | AstraZeneca |
| Year approved | 2012 | 2003 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $90M | $45M |
| Common side effects | Atrial fibrillation, Bleeding risk, Joint pain, Swelling | Muscle pain, Headache, Liver problems, Increased blood sugar |
Frequently asked questions
Is Vascepa or Crestor better?
Neither is universally "better." Vascepa (icosapent ethyl) and Crestor (rosuvastatin) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vascepa and Crestor?
Vascepa is a Omega-3 Fatty Acid (EPA) made by Amarin, while Crestor is a Statin made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vascepa has the larger estimated TV advertising budget of the two.